题目内容

In October 2015, FDA approved Imlygic (talimogene laherparepvec) that is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with ____________ recurrent after initial surgery.

查看答案

搜索结果不匹配？点我反馈

更多问题

The most commonly reported adverse drug reactions (≥25%) in Imlygic-treated patients are _________, chills, pyrexia, nausea, influenza-like illness, and injection site pain.

Treatment with Kymriah has the potential to cause severe side effects. It carries a boxed warning for __________, which is a systemic response to the activation and proliferation of CAR T-cells causing high fever and flu-like symptoms, and for neurological events.

Other severe side effects of Kymriah include _________________, low blood pressure (hypotension), acute kidney injury, fever, and decreased oxygen (hypoxia). Most symptoms appear within one to 22 days following infusion of Kymriah.

Cell-based gene therapy techniques remove cells from the patient in order to genetically alter them then ______________ them to the patient's body.